Open AccessTumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC
Author(s) -
Meghan J. O’Melia,
Margaret P. Manspeaker,
Susan N. Thomas
Publication year - 2021
Publication title -
cancer immunology, immunotherapy/cancer immunology and immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.389
H-Index - 115
eISSN - 1432-0851
pISSN - 0340-7004
DOI - 10.1007/s00262-020-02792-5
Subject(s) - tumor microenvironment , lymphatic system , immune system , priming (agriculture) , t cell , cd8 , immunology , cytotoxic t cell , cancer research , antigen , immunotherapy , immune checkpoint , biology , cancer immunotherapy , medicine , biochemistry , botany , germination , in vitro
Triple negative breast cancer (TNBC) is a significant clinical problem to which immunotherapeutic strategies have been applied with limited success. Using the syngeneic E0771 TNBC mouse model, this work explores the potential for antitumor CD8 + T cell immunity to be primed extratumorally in lymphoid tissues and therapeutically leveraged. CD8 + T cell viability and responses within the tumor microenvironment (TME) were found to be severely impaired, effects coincident with local immunosuppression that is recapitulated in lymphoid tissues in late stage disease. Prior to onset of a locally suppressed immune microenvironment, however, CD8 + T cell priming within lymph nodes (LN) that depended on tumor lymphatic drainage remained intact. These results demonstrate tumor-draining LNs (TdLN) to be lymphoid tissue niches that support the survival and antigenic priming of CD8 + T lymphocytes against lymph-draining antigen. The therapeutic effects of and CD8 + T cells response to immune checkpoint blockade were furthermore improved when directed to LNs within the tumor-draining lymphatic basin. Therefore, TdLNs represent a unique potential tumor immunity reservoir in TNBC for which strategies may be developed to improve the effects of ICB immunotherapy.